Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

February 7, 2024

https://www.globenewswire.com/news-release/2024/02/08/2825648/0/en/Tenax-Therapeutics-Enrolls-First-Patient-in-Phase-3-LEVEL-Study-Evaluating-TNX-103-Oral-Levosimendan-for-the-Treatment-of-Pulmonary-Hypertension-in-Heart-Failure-with-Preserved-Eje.html

Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study

LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research centers with large PH-HFpEF populations

Read more at globenewswire.com

Related news for (TENX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.